XTalks

JANUARY 16, 2025

Sling Therapeutics has positive topline results from its Phase IIb/III LIDS clinical trial evaluating its oral small-molecule therapy linsitinib for the treatment of thyroid eye disease (TED). Ninety patients in the trial were randomized to receive one of two doses of linsitinib or placebo.

Trials 59

Trials Clinical Trials Clinical Trials Insulin 59

BioSpace

JUNE 25, 2023

A year after treatment, Vertex’s VX-880 has eliminated the need for insulin injections in two Type 1 diabetes patients in a Phase I/II clinical trial of its investigational stem cell-based therapy.

Insulin 77

Insulin Trials Clinical Trials Clinical Trials 77

Rethinking Clinical Trials

AUGUST 18, 2022

The Trial Innovation Network Recruitment Innovation Center aims to positively impact human health by improving participant enrollment and retention in multi-center clinical trials. It leads to physiological changes, it leads to insulin resistance, changes in your immunology. There is plenty of data that shows that.

Clinical Trials 100

Clinical Trials Clinical Trials Trials Insulin 100

XTalks

APRIL 29, 2021

Multiple studies have confirmed that conducting clinical trials with a diverse range of ethnicities, genders, ages, and lifestyles is essential, since these factors can impact a treatment’s effectiveness among different groups. Despite this, ethnic minorities are underrepresented in clinical trials.

Clinical Trials 95

Clinical Trials Clinical Trials Trials Drugs 95

Pharmaceutical Technology

JULY 12, 2022

VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy of Vertex for T1D. It has attained proof-of-concept with favourable safety and efficacy data from an ongoing Phase I/II clinical trial which is currently enrolling and dosing participants.

Gene Therapy 276

Gene Therapy Insulin Manufacturing Clinical Trials 276

Pharmaceutical Technology

FEBRUARY 24, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. LAI-287 + semaglutide) overview A fixed dose combination of GLP-1 analogue semaglutide and LAI-287, long-acting basal insulin is under development for the treatment of type 2 diabetes.

Insulin 182

Insulin Hormones Drugs Clinical Trials 182

XTalks

SEPTEMBER 2, 2020

NAFLD is part of the metabolic syndrome that is characterized by diabetes, or pre-diabetes (insulin resistance), which includes being overweight or obese, elevated blood lipids such as cholesterol and triglycerides, as well as high blood pressure. VK2809 and the VOYAGE Trial. NASH may result in severe liver scarring and cirrhosis.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Insulin 98

XTalks

APRIL 22, 2022

Flow cytometric receptor occupancy assays are being increasingly used in preclinical and clinical studies. Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. The Benefits of Receptor Occupancy in Clinical Trials.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

XTalks

NOVEMBER 21, 2024

These gut hormones are released in response to nutrient intake and play a crucial role in the incretin effect, which enhances insulin secretion. Participants were selected based on their prediabetic status, and the trial compared tirzepatide with a placebo.

Sales 105

Sales Insulin Drugs Trials 105

Antidote

JULY 9, 2024

Though clinical trials are often discussed in the context of medications and therapies, the devices that administer these medications must also be approved by the FDA before they can be released to market.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Insulin 52

STAT News

SEPTEMBER 29, 2022

Keeping blood glucose in a healthy range requires a constant stream of calculations: counting the carbs in each meal, and then finding the right dose of insulin to balance them out. In the last several years , automated insulin delivery has helped many patients with type 1 diabetes avoid harmful dips and surges in their blood sugar.

Insulin 126

Insulin Clinical Trials Clinical Trials Trials 126

Pharmaceutical Technology

DECEMBER 12, 2022

Pipeline therapies within the cardiometabolic space have recently gathered interest following the 20th World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) Hybrid Conference, which took place on 1–3 December.

Compliance 264

Compliance Insulin Marketing Trials 264

Pharmaceutical Technology

JANUARY 10, 2023

Hailed as a breakthrough, Tzield’s approval marks the first of its kind to be introduced since the discovery of insulin, which won the 1923 Nobel Prize in the category of Physiology or Medicine. These therapies work by reprogramming the immune system, preventing it from attacking and eradicating insulin-producing cells in the pancreas.

Insulin 246

Insulin FDA Approval Research Development 246

pharmaphorum

OCTOBER 4, 2022

Danish company Novo Nordisk have announced positive results from the ONWARDS 5 phase 3 trial, with once-weekly insulin icodec demonstrating superior reduction of HbA1 in people with type 2 diabetes, in combination with a dosing guide app.

Insulin 59

Insulin Trials Clinical Trials Clinical Trials 59

BioPharma Reporter

JANUARY 29, 2024

Synthetic biology company rBIO has completed all required analytical characterizations of its insulin biosimilar, R-biolin.

Insulin 52

Insulin Clinical Trials Clinical Trials Trials 52

Rethinking Clinical Trials

AUGUST 22, 2022

The COVID-OUT Trial is a remotely delivered, Phase 3, de-centralized clinical trial at 6 participating institutions to see if Ivermectin, Metformin or Fluvoxamine would prevent severe COVID-19. Initially, the randomization of the trial was 1:1 Metformin or Placebo. The primary outcome of the trial was negative.

Trials 100

Trials Clinical Trials Clinical Trials Insulin 100

NY Times

NOVEMBER 27, 2021

A new treatment using stem cells that produce insulin has surprised experts and given them hope for the 1.5 million Americans living with the disease.

Insulin 145

Insulin Clinical Trials Clinical Trials Drugs 145

BioPharma Reporter

SEPTEMBER 12, 2024

New data from the QWINT clinical trial may get Eli Lilly closer to bringing a once-weekly insulin injection to the US, following the FDAâs rejection of Novo Nordiskâs own weekly insulin formulation earlier this year.

Insulin 52

Insulin Clinical Trials Clinical Trials Trials 52

The Pharma Data

APRIL 28, 2022

Novo Nordisk today announced headline results from the ONWARDS 2 trial, a phase 3a, 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs insulin degludec in 526 people with type 2 diabetes switching from daily insulin. events per patient-year exposed to insulin degludec.

Insulin 52

Insulin Trials Clinical Trials Clinical Trials 52

Pharma Times

DECEMBER 21, 2023

The new guidance followed a review of a clinical trial and real-world evidence by the University of Warwick and Warwick Medical School, funded by the National Institute for Health and Care Research. The new hybrid closed loop systems have proven to be more effective in maintaining healthy blood glucose levels than standard care.

Insulin 122

Insulin Clinical Trials Clinical Trials Production 122

BioTech 365

SEPTEMBER 20, 2021

Arecor Announces Positive Headline Results From First Phase i Clinical Trial of At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Candidate for Diabetes Arecor Announces Positive Headline Results From First Phase i Clinical Trial of At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Candidate for Diabetes … Continue reading →

Insulin 40

Insulin Clinical Trials Clinical Trials Trials 40

BioTech 365

MAY 13, 2021

Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-024, a Novel Precision Medicine Product Candidate for Patients with Severe Insulin Resistant Diabetic Nephropathy (DN) Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-024, a Novel Precision Medicine Product Candidate for … Continue reading →

Insulin 40

Insulin Clinical Trials Clinical Trials Medicine 40

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. Diamyd Medical is a clinical-stage biopharmaceutical company that develops therapies for type 1 diabetes. The DIAGNODE-2 Trial.

Vaccination 103

Vaccination Vaccine Insulin Trials 103

Pharmaceutical Technology

MARCH 29, 2023

This programme has now proceeded into a Phase I clinical trial. Last May, Evotec and Sernova signed an exclusive worldwide strategic collaboration to develop a cell therapy for treating individuals with insulin-dependent diabetes.

Clinical Trials 130

Clinical Trials Clinical Trials Insulin Medicine 130

pharmaphorum

SEPTEMBER 22, 2022

Insulin has been used to manage diabetes for a century, and while many advances have been made for people with both type 1 and type 2 diabetes – many more continue to be made. The post How a once-weekly insulin could disrupt diabetes management – the pharmaphorum podcast appeared first on.

Insulin 52

Insulin Clinical Trials Clinical Trials Trials 52

pharmaphorum

MAY 16, 2022

The findings were made via Lilly’s SURPASS phase 3 global clinical development programme, which comprised studies ranging from 40 to 52 weeks. These examined Mounjaro in 5mg, 10mg and 15 mg doses in five clinical trials, used either as a stand-alone therapy or as an add-on to other diabetes medicines. more than insulin glargine.

FDA Approval 115

FDA Approval Insulin Drugs Hormones 115

Scienmag

JANUARY 26, 2021

publishers New Rochelle, NY, January 26, 2021–Hybrid closed-loop insulin therapy improved glycemic control in adolescents and young adults with type 1 diabetes. These outcomes, derived from the International Diabetes Closed-Loop (iDCL) Trial, are reported in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT).

Insulin 55

Insulin Trials Gene Therapy Clinical Trials 55

XTalks

NOVEMBER 22, 2022

In clinical trials, the treatment delayed stage 3 disease onset for about two years compared with the placebo. Type 1 diabetes, also known as insulin-dependent or juvenile diabetes, is an autoimmune disease that occurs when the body is unable to make enough insulin due to destruction of the beta insulin-producing cells in the pancreas.

Insulin 97

Insulin Drugs FDA Approval Immune Response 97

Pharmaceutical Technology

MARCH 1, 2023

More than a century after an individual with type 1 diabetes was treated with insulin for the first time, the FDA approved Tzield, the first and only treatment to delay the onset of type 1 diabetes. Also in this month’s issue, we take a look at the innovative type 1 diabetes therapy by Provention Bio called Tzield.

Production 130

Production Insulin FDA Approval Pharma Production 130

XTalks

MARCH 8, 2021

Eli Lilly (NASDAQ: LLY ) reported late last week that its investigational diabetes injection, tirzepatide, demonstrated superiority to Novo Nordisk’s (NASDAQ: NVO ) ozempic (semaglutide) in a Phase III trial. GLP-1 receptor agonists lower blood glucose levels by increasing the production of insulin. SURPASS-2 Clinical Trial.

Insulin 98

Insulin Hormones Clinical Trials Clinical Trials 98

XTalks

DECEMBER 13, 2024

Zealand Pharma has commenced its global Phase IIb ZUPREME-1 trial, enrolling the first participant to evaluate petrelintide, a long-acting amylin analog, as a potential investigational treatment for people with overweight or obesity. And among its many obesity drugs in clinical trials, Eli Lillys amylin analog eloralintide is in Phase II.

Drugs 102

Drugs Hormones Trials Clinical Trials 102

XTalks

DECEMBER 15, 2022

In September 2021, the US Food and Drug Administration (FDA) issued a partial US clinical hold on the phase III DIAGNODE-3 clinical trial of the drug. ” The trial DIAGNODE-3 is approved and currently recruiting patients in eight countries in Europe. . The US Clinical Hold on the Diamyd Trial is Lifted, Now What?

Clinical Trials 97

Clinical Trials Clinical Trials Vaccination Vaccine 97

XTalks

APRIL 29, 2022

Eli Lilly announced that its obesity drug tirzepatide has scored favorably in a late-stage clinical trial, with results showing that people who took the drug lost an average of 50 pounds, or 21 percent, of their body weight compared to placebo. percent and 22.5 percent, respectively, compared to placebo.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

pharmaphorum

APRIL 9, 2021

The issues are holding up discussions between the agency and company about labeling and post-marketing requirements for teplizumab, and are concentrated around the pharmacokinetics data for the antibody, and whether it is comparable to the drug that its original developer Eli Lilly entered into clinical trials.

Antibody 98

Antibody Insulin Trials Production 98

Pharmaceutical Technology

APRIL 17, 2023

An insulin-like growth factor-1 receptor inhibitor, Tepezza is claimed to be the first and only medicine to receive approval from the FDA to treat TED, a rare progressive, debilitating and potentially vision-threatening autoimmune disease.

FDA Approval 130

FDA Approval Drugs Insulin Clinical Trials 130

XTalks

JULY 17, 2024

Sweden-based biotech Camurus shared positive Phase III trial data for CAM2029, one of its lead candidates, in patients with the rare hormonal disorder acromegaly. Octreotide is a synthetic analog of somatostatin, a hormone in the body that inhibits the release of several other hormones, including growth hormone (GH), glucagon and insulin.

Trials 59

Trials Hormones Clinical Trials Clinical Trials 59

XTalks

DECEMBER 11, 2024

The companys lead innovation is an implantable bio-hybrid organ pouch, which is currently in an ongoing Phase I/II clinical trial. Prior to heading Sernova, Jonathan served as President and CEO of Revolo Biotherapeutics where he took the company through multiple financings and two Phase II clinical trials.

Life Science 52

Life Science Clinical Trials Clinical Trials Trials 52